top of page

Guidelines for breast cancer treatment during COVID-19 pandemic

Using TARGIT-IORT during lumpectomy for breast cancer patients could be of special relevance during the current COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2.  By taking TARGIT-IORT during lumpectomy, subsequent travel for postoperative radiotherapy could be entirely avoided. and the risk of viral exposure greatly reduced. Therefore, TARGIT-IORT for breast cancer has been especially recommended in national and international guidelines during these trying times.

During the COVID-19 pandemic, new guidelines for treatment of beast cancer  and radiotherapy have recommend using TARGIT-IORT because it would save patients the daily travel (and viral exposure) to radiotherapy departments:

Global radiation oncology's targeted preparedness for COVID-19 

“where the technology is available the use of IORT may obviate the need for any further outpatient treatment and should be considered an option ..” 


British Association of Cancer Surgery (BASO~ACS)

German University Hospitals

Italian Association of Radiotherapy and Clinical Oncology

Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group

Implementation of breast cancer continuum of care in low- and middle-income countries during the COVID-19 pandemic

The impact of COVID-19 on and recommendations for breast cancer care: the Singapore experience

China is increasing its use of TARGIT-IORT #breastcancer by equipping more centres with the TARGIT-IORT equipment 



Click here to see the national and international guidelines recommending TARGIT-IORT for breast cancer

bottom of page